Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

@article{Durbecq2004TopoisomeraseIIAE,
  title={Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.},
  author={Virginie Durbecq and Marianne Paesmans and F{\'a}tima Cardoso and Christine Desmedt and Angelo di Leo and Stephen R. Chan and K. O. Friedrichs and Tam{\'a}s Pint{\'e}r and Simon van Belle and Elizabeth E Murray and Istv{\'a}n Bodrogi and Euan Thomas Walpole and Bernard Lesp{\'e}rance and Stefan Korec and John Crown and Peter Simmonds and Thimothy J Perren and Juliens Leroy and Ghizlane Rouas and Christos Sotiriou and Martine J. Piccart and Denis P Larsimont},
  journal={Molecular cancer therapeutics},
  year={2004},
  volume={3 10},
  pages={1207-14}
}
PURPOSE The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel. EXPERIMENTAL DESIGN Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m(2) q3wks) with docetaxel (100 mg/m(2) q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1). RESULTS Topo-II status was… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…